Àü½Å±â ¼Ò¼¼Æ÷ Æó¾Ï¿¡ ´ëÇÑ EP ÈÇпä¹ý°ú EP/CAV ±³´ëÈÇпä¹ýÀÇ ºñ±³ ¿¬±¸
A Randomized Comparison of EP Sequential Chemotherapy Verus EP/CAV Alternating Chemotherapy for Extensive-stage Small-cell Lung Cancer
´ëÇѾÏÇÐȸÁö 1994³â 26±Ç 5È£ p.786 ~ p.792
¼Ã¢ÀÎ(Suh Chang-In) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Ú¿µ¼®(Park Young-Suk) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ °µ¿¼º½Éº´¿ø ³»°ú
Á¤±â¼®(Chung Ki-Suck) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ °µ¿¼º½Éº´¿ø ³»°ú
Çã´ë¼®(Heo Dae-Seok) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹æ¿µÁÖ(Bang Young-Jue) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è³ë°æ(Kim Noe-Kyeong) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
The present randomized, prospective study was designed to assess whether alternating etoposide. Cisplatin (EP) and cyclophosphamide, adriamycin, vincristine (CAV) is better than etoposide, cisplatin (EP) chemotherapy in improving response, survival and remission duration in 62 evaluable patients having extensive-stage small-cell lung cancer. (SCLC) There were no significant differences in treatment outcome for EP alone, EP/CAV in terms of response rate (65% versus 75%), complete response rate (9% versus 7%), remission duration (5 months versus 5 months) or median survival (10 months versus 11 months). Severe myelosuppression was more common in EP/CAV alternating treatment. The EP/CAV alternating regimen and EP alone regimen can be considered equivalently effective induction therapies in extensive SCLC and these two regimens are, to some degree, cross resistant. Alternating therapy provides no therapeutic advantage with more myelosuppression compared to the EP alone chemotherapy and should not be considered as standard treatment in this clinical setting.
Å°¿öµå
Small cell lung cancer, combination chemotherapy
KMID :
0360319940260050786
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
There were no significant differences in treatment outcome for EP alone, EP/CAV in terms of response rate (65% versus 75%), complete response rate (9% versus 7%), remission duration (5 months versus 5 months) or median survival (10 months versus 11 months).